CCCCEHA spotlight time
C4 Therapeutics took the stage at the European Hematology Association 2026 Congress and brought along some early-but-interesting Phase 1 data for cemsidomide, its IKZF1/3 degrader in multiple myeloma.
At the 100 µg recommended Phase 2 dose, the drug showed a 53% overall response rate in a heavily pretreated relapsed/refractory population. That’s not just "the patients sort of looked better" territory — the company says the readout included complete responses and even MRD-negative status, which is the biotech equivalent of hearing your friend say, "No, really, this one might be different."
Why investors care
For a small-cap drug developer, clinical data is the whole ballgame. Positive early efficacy in a tough-to-treat cancer can:
- De-risk the program a bit more
- Support future trial design and dose selection
- Give investors a fresh reason to believe the asset could stand out in a crowded multiple myeloma field
Of course, Phase 1 is still Phase 1. This is the appetizer, not the main course. But when a company can point to responses in a heavily pretreated group, it helps keep the narrative from drifting into the biotech graveyard of "promising preclinical idea, please clap."
Big picture
C4 now has a data point that can help it keep the market’s attention. The next question is whether cemsidomide can turn this early promise into cleaner, larger, more durable results as the program moves forward.